According to the Legislative Budget Board (LBB), the fiscal implications of HB 3269 are projected to result in a net cost to the state’s General Revenue Fund of approximately $3.66 million over the 2026–2027 biennium. According to the LBB, the Health and Human Services Commission (HHSC) would require $2.96 million in fiscal year 2026 to establish the Rita Littlefield Chronic Kidney Disease Centralized Resource Center, with $705,024 in ongoing annual costs beginning in 2027.

These costs are primarily associated with staffing, technology infrastructure, and professional services. The bill anticipates hiring two full-time employees to oversee the resource center and maintain a new clinical trials registry. Additionally, HHSC would need to develop a dedicated website for patient access and interaction, which would include building new system infrastructure and supporting digital services. Technology startup costs alone are estimated at over $2.15 million for FY 2026, with about $170,000 annually thereafter for ongoing system maintenance.

Another major cost factor is a planned partnership with an institute of higher education (IHE) to provide medically accurate content, conduct peer reviews, and assist with outreach campaigns. This partnership is projected to cost $550,000 in FY 2026 and $300,000 in FY 2027, including one-time implementation expenses.

Despite the financial investment, the bill does not appropriate funds but would serve as enabling legislation for future appropriations. It also allows HHSC to seek grants, gifts, and donations, potentially offsetting public costs. There are no anticipated fiscal impacts on local governments. Overall, while the bill carries a modest budgetary cost, it offers potential long-term savings and improved health outcomes through early detection and education regarding chronic kidney disease.

While HB 3269 is well-intentioned in addressing the challenges posed by chronic kidney disease, it expands the authority and functions of the Health and Human Services Commission (HHSC) by creating a new government-run program: the Rita Littlefield Chronic Kidney Disease Centralized Resource Center. This expansion involves new personnel, digital infrastructure, an ongoing clinical trials registry, and public outreach efforts. While limited in scale, this represents a clear increase in the size and scope of state government—establishing a new permanent function within a health agency that already administers numerous programs.

In terms of fiscal impact, the bill would cost an estimated $3.66 million in General Revenue over the first two years, with continued annual operational costs thereafter. Though the bill permits HHSC to seek private grants and donations, these funds are neither guaranteed nor sufficient to offset the taxpayer obligation. This new spending occurs without sunset provisions, measurable benchmarks, or requirements to demonstrate cost-effectiveness or outcomes, raising questions about long-term budget sustainability and program accountability.

Importantly, HB 3269 does not impose direct regulations on individuals or businesses, but it does create a taxpayer-funded alternative to private efforts already active in this space. Numerous hospitals, nonprofit health organizations, medical research institutions, and patient advocacy groups already offer robust resources, education, and trial access related to kidney disease. By entering this space, the state risks duplicating existing services and potentially displacing or undermining private initiatives that operate more flexibly and without taxpayer support.

Additionally, the creation of a disease-specific government resource center risks setting a precedent for future condition-based programs, leading to mission creep in public health policy. If the state creates an official office for kidney disease, other interest groups could reasonably demand similar treatment for diabetes, heart disease, or other chronic conditions—each of which affects large populations and could be argued to merit centralized information hubs. This trajectory could lead to a gradual and unchecked expansion of government responsibility in public health education.

In conclusion, while improving public awareness of kidney disease is a worthwhile goal, HB 3269 assigns that task to government in a way that stretches the boundaries of limited governance, increases the burden on taxpayers, and duplicates existing civil society efforts. Lawmakers committed to preserving fiscal restraint, government discipline, and the primacy of private solutions in public health should oppose this legislation. Texas Policy Research recommends that lawmakers vote NO on HB 3269.

• Individual Liberty: The bill enhances individual liberty in one sense by providing Texans—especially those with limited access to healthcare—with voluntary, bilingual access to information about kidney disease, treatment options, and clinical trials. This access empowers people to make more informed decisions about their health. However, creating a state-run information center presumes that the government is best suited to provide this service, which may undermine liberty in the long term by increasing dependence on government over private initiative.
• Personal Responsibility: By offering free educational resources and health screening information, the bill encourages early detection and proactive health management. These tools could support personal responsibility by helping people take charge of their health. Still, critics may argue that government involvement in providing these services can blur the line between enabling self-help and substituting for it, especially when similar resources are already available in the private sector.
• Free Enterprise: The creation of a government-funded center may compete with or displace private and nonprofit efforts already delivering similar services. Hospitals, patient advocacy organizations, and medical providers currently disseminate education and coordinate clinical trials. By establishing a centralized public entity, the state risks crowding out innovation or discouraging private-sector investment in outreach or education on kidney disease.
• Private Property Rights: The bill does not affect private property rights directly. It does not authorize eminent domain, new regulations, or any form of property restriction. Its focus is administrative and informational.
• Limited Government: This is where the bill most clearly diverges from liberty principles. The bill grows the size and scope of government by establishing a new state program with dedicated staffing, web infrastructure, and budget. It does so in a policy area—public health education—that could reasonably be fulfilled by civil society or market actors. It also introduces new, ongoing costs to the state without hard accountability or sunset mechanisms. This violates the principle that government should be limited to core functions and avoid duplicating private-sector roles.

• SB 2089 (Same As)